Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.51T +27.9% |
| Revenue (ttm) | 496.83B +0.3% |
| Net Income | 67.04B +12.0% |
| EPS | 128.07 +13.3% |
| Shares Out | 523.49M |
| PE Ratio | 22.53 |
| Forward PE | 19.25 |
| Dividend | 70.00 (2.43%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 2,784,700 |
| Average Volume | 2,037,275 |
| Open | 2,836.00 |
| Previous Close | 2,812.50 |
| Day's Range | 2,817.50 - 2,912.00 |
| 52-Week Range | 2,034.00 - 2,912.00 |
| Beta | 0.01 |
| RSI | 70.16 |
| Earnings Date | Feb 9, 2026 |
About Kyowa Kirin
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachro... [Read more]
Financial Performance
In 2025, Kyowa Kirin's revenue was 496.83 billion, an increase of 0.26% compared to the previous year's 495.56 billion. Earnings were 67.04 billion, an increase of 11.98%.
Financial StatementsNews
Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Roctinlimab
Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Roctinlimab
Amgen ends collaboration agreement with Kyowa Kirin for eczema asset
Amgen ends roctinlimab deal with Kyowa Kirin, returning full rights. Read more here.
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Co., Ltd . and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration. • Amgen stock is trading at elevated levels. Where ...
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.
Amgen Inc. (AMGN) Announces Termination of License and Collaboration Agreement with Kyowa Kirin
Amgen Inc. (AMGN) Announces Termination of License and Collaboration Agreement with Kyowa Kirin
Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab
(RTTNews) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker regaining full control ...
Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Rocatinlimab
Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Rocatinlimab
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors' decision to appoint Abdul Mullick,...
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential for...
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceu...
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
The licensed small molecule program aims to address significant unmet needs for autoimmune diseases . Program adds to Boehringer's pipeline and its commitment to deliver breakthrough therapies for pa...
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
– First and only disease-modifying therapy for the treatment of eligible children with MLD also receives Orphan Drug Designation and Priority Review in the Kingdom of Saudi Arabia – – First and only d...
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary Syndrome First-of-its kind tool to guide HCPs on what to consider when staging patients...
Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript
Kyowa Kirin Co., Ltd. (OTCPK:KYKOF) Q2 2025 Earnings Conference Call July 31, 2025 9:00 PM ET Company Participants Abdul Mullick - Representative Director, President & Chief Operating Officer Masashi ...
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO , July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN
-Agreement extends one of the world's most enduring alliances for drug discovery- -Landmark discoveries from partnership have led to novel drug candidates, including an immunotherapy for moderate to s...
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
PRINCETON, N.J. , Feb. 26, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
GALASHIELS & MARLOW, England & BAAR, Switzerland--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the C...
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
Longstanding relationship strengthens innovation, providing diverse stakeholders access to advanced AI-driven insights to accelerate therapeutic discovery and development Longstanding relationship str...
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics announced today that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for diseases w...
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company
TOKYO--(BUSINESS WIRE)--Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto.) (TOKYO:4151) today announced that Masashi Miyamoto, Ph.D. will ...
Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024
GALASHIELS & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim find...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET Pro...
Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting
One oral presentation and nine posters will shed light on real-world experiences of people living with XLH and the impact of burosumab treatment TOKYO , Sept. 19, 2024 /PRNewswire/ -- Kyowa Kirin Co.,...